共查询到20条相似文献,搜索用时 875 毫秒
1.
2.
近十年免疫疗法在肿瘤的治疗中取得了突破性进展,导致肿瘤治疗的范式转变。然而大多数患者并不能从中获益,如何提高患者免疫治疗的应答率是亟待解决的热点问题。免疫疗法的成功有赖于机体免疫效应细胞的活化及杀伤效应。然而,在肿瘤微环境严苛的代谢和营养应激下,免疫细胞的功能常处于紊乱状态,导致抗肿瘤免疫应答受损。因此,通过靶向肿瘤代谢重塑免疫微环境,恢复抗肿瘤免疫应答,有望在与免疫疗法的联合应用中取得协同效应。本文着重探讨代谢重编程及其代谢产物如何调节抗肿瘤免疫应答,旨在为肿瘤免疫治疗提供新的思路和方法。 相似文献
3.
近十年免疫疗法在肿瘤的治疗中取得了突破性进展,导致肿瘤治疗的范式转变。然而大多数患者并不能从中获益,如何提高患者免疫治疗的应答率是亟待解决的热点问题。免疫疗法的成功有赖于机体免疫效应细胞的活化及杀伤效应。然而,在肿瘤微环境严苛的代谢和营养应激下,免疫细胞的功能常处于紊乱状态,导致抗肿瘤免疫应答受损。因此,通过靶向肿瘤代谢重塑免疫微环境,恢复抗肿瘤免疫应答,有望在与免疫疗法的联合应用中取得协同效应。本文着重探讨代谢重编程及其代谢产物如何调节抗肿瘤免疫应答,旨在为肿瘤免疫治疗提供新的思路和方法。 相似文献
4.
5.
6.
肿瘤免疫治疗是继手术、化疗、放疗后的第四种疗法,在部分上皮性肿瘤和血液性肿瘤的治疗中取得较大突破,但不良反应常见甚至比较严重,在部分实体肿瘤中的应答率也不够理想。随着基因组学和代谢组学技术的成熟,人们逐渐认识到肠道菌群在肿瘤发展与治疗中的作用。菌群可能通过调节宿主免疫系统和肿瘤微环境等方式影响肿瘤免疫,部分细菌通过激活免疫起到协助对抗肿瘤的作用,而有些细菌则介导免疫抑制帮助癌细胞逃避免疫系统的杀伤。越来越多的研究揭示肿瘤免疫治疗的效果和并发症与患者肠道菌群组成有关,对治疗敏感或易发生不良反应的患者肠道菌群组成有一定特征。这些特征可能作为生物标志物来预测免疫治疗的预后,也可能被开发为“免疫增效剂”(如Akk菌和双歧杆菌)来辅助免疫治疗。部分临床和临床前研究已证明包括菌群移植在内的微生物干预能一定程度上提高免疫治疗的敏感性或减轻不良反应。随着基因编辑技术和纳米技术的发展,有助于免疫治疗的工程细菌的设计开发成为了新的研究热点。基于肠道菌群和免疫治疗的关系,正确挖掘微生物信息、开发合理可行的微生物干预手段,有希望在很大程度上优化肿瘤免疫疗法,为肿瘤治疗带来新的突破。 相似文献
7.
8.
宫颈癌严重威胁全球女性的生命健康,晚期宫颈癌治疗手段有限,5年生存率不到20%,是妇科肿瘤的巨大挑战。免疫治疗是晚期宫颈癌患者的重要治疗手段之一,包括免疫检查点抑制剂、治疗性疫苗和过继性T细胞免疫疗法等,但免疫治疗耐药性使部分患者无应答而效果不佳。因此,迫切需要深入研究和探讨免疫耐药的机制从而改善耐药,现归纳总结了近年有关宫颈癌中免疫耐药机制的相关研究,主要分为肿瘤内在因素和外在免疫环境改变等因素,并介绍针对免疫耐药提出的应对措施及进展。 相似文献
9.
肿瘤免疫微环境(TIME)是肿瘤细胞得以生存和发展的复杂环境,其组成成分及相关特征在调节肿瘤的发生和发展中发挥重要作用,并影响不同免疫疗法的临床疗效。TIME的研究为实体瘤诊疗开辟了一条新的路径,因此针对TIME的治疗策略具有发展前景且成为探索方向,以帮助指导和改善实体瘤的治疗。本文基于FOWLER团队确认的TIME四分型理论,进一步阐述不同分型的TIME特征及潜在可适用的免疫治疗方式,对目前基于TIME分型的肿瘤免疫治疗选择提供指导。同时提出在成像引导的测序等新技术协助下,新的生物标志物、TIME分型理论和治疗靶点的涌现,为实体瘤免疫疗法赋予光明前景。在新的疗法不断出现的同时,基于TIME的免疫治疗研究方向仍应尽可能提前关口,以实现肿瘤早诊早治的目的。 相似文献
10.
RNA在多种生理和病理过程中起着至关重要的作用。在过去的几十年中,研究人员已经设计出多种类型的RNA及 其衍生体,并应用于不同的生物学领域。研究证实,RNA分子在肿瘤的生长、转移、代谢和免疫逃逸等方面发挥着重要作用。基 于肿瘤相关RNA的研究和相关技术的应用,RNA已经被设计应用于肿瘤免疫治疗之中。此外,作为肿瘤免疫治疗的工具,RNA 可以与其他类型的免疫疗法结合使用,例如免疫检查点抑制剂、树突状细胞回输治疗以及嵌合抗原受体T细胞免疫疗法等。在 综述中,论述了各种RNA工具(包括RNA适配体、mRNA疫苗和RNA溶瘤病毒)在肿瘤免疫治疗中应用的研究进展,总结了这些 RNA工具治疗肿瘤的优点和缺点,并展望了RNA及其衍生体未来在肿瘤免疫治疗中的潜在临床应用。 相似文献
11.
12.
Immunotherapy has revolutionized cancer treatment for several hematologic and solid organ malignancies; however, pancreatic cancer remains unresponsive to conventional immunotherapies. Several characteristics of pancreatic cancer present challenges to successful treatment with immunotherapy, including its aggressive biology, poor immunogenicity, and abundant desmoplastic stroma which can impede effector T cell infiltration and promote an immunosuppressive microenvironment. In this review, we evaluate the current understanding of the immune and stromal landscapes of pancreatic cancer, discuss the successes and failures of stroma-targeted therapies, and highlight how stroma-directed therapies may be synergistic with immunotherapy. 相似文献
13.
Edwin Nieblas-Bedolla Naema Nayyar Mohini Singh Ryan J. Sullivan Priscilla K. Brastianos 《The oncologist》2021,26(3):231-241
Brain metastases account for considerable morbidity and mortality in patients with cancer. Despite increasing prevalence, limited therapeutic options exist. Recent advances in our understanding of the molecular and cellular underpinnings of the tumor immune microenvironment and the immune evasive mechanisms employed by tumor cells have shed light on how immunotherapies may provide therapeutic benefit to patients. The development and evolution of immunotherapy continue to show promise for the treatment of brain metastases. Positive outcomes have been observed in several studies evaluating the efficacy and safety of these treatments. However, many challenges persist in the application of immunotherapies to brain metastases. This review discusses the potential benefits and challenges in the development and use of checkpoint inhibitors, chimeric antigen receptor T‐cell therapy, and oncolytic viruses for the treatment of brain metastases. Future studies are necessary to further evaluate and assess the potential use of each of these therapies in this setting. As we gain more knowledge regarding the role immunotherapies may play in the treatment of brain metastases, it is important to consider how these treatments may guide clinical decision making for clinicians and the impact they may have on patients.Implications for PracticeImmunotherapies have produced clinically significant outcomes in early clinical trials evaluating patients with brain metastases or demonstrated promising results in preclinical models. Checkpoint inhibitors have been the most common immunotherapy studied to date in the setting of brain metastases, but novel approaches that can harness the immune system to contain and eliminate cancer cells are currently under investigation and may soon become more common in the clinical setting. An understanding of these evolving therapies may be useful in determining how the future management and treatment of brain metastases among patients with cancer will continue to advance. 相似文献
14.
胰腺癌(胰腺导管腺癌)是一种恶性程度较高,诊断和治疗都较困难的消化系统恶性肿瘤。近年来,肿瘤免疫治疗在多种肿瘤中如黑色素瘤、膀胱癌、乳腺癌、非小细胞肺癌和肾癌等均取得了令人振奋的治疗效果,但是胰腺癌的免疫治疗策略尚在不断探索中。目前针对胰腺癌独特的肿瘤微环境设计了多种免疫治疗策略,包括强化/提高自身免疫反应(免疫调节剂、单克隆抗体、肿瘤疫苗和细胞治疗)以及抑制肿瘤免疫逃逸(免疫检查点抑制剂和肿瘤微环境)等。本文就胰腺癌免疫治疗的研究进展进行综述,着重探讨PD-1/PD-L1抑制剂在胰腺癌中的应用,并分析免疫治疗联合其他方式治疗胰腺癌的前景。 相似文献
15.
Active immunotherapy targeting dendritic cells (DCs) has shown great promise in preclinical models and in human clinical trials for the treatment of malignant disease. Sipuleucel-T (Provenge, Dendreon, Seattle, WA), which consists of antigen-loaded dendritic cells (DCs), recently became the first targeted therapeutic cancer vaccine to be approved by the US Food and Drug Administration (FDA). However, ex vivo therapies such as Provenge have practical limitations and elicit an immune response with limited scope. By contrast, live-attenuated Listeria monocytogenes (Lm) naturally targets DCs in vivo and stimulates both innate and adaptive cellular immunity. Lm-based vaccines engineered to express cancer antigens have demonstrated striking efficacy in several animal models and have resulted in encouraging anecdotal survival benefit in early human clinical trials. Two different Lm-based vaccine platforms have advanced into phase II clinical trials in cervical and pancreatic cancer. Future Lm-based clinical vaccine candidates are expected to feature polyvalent antigen expression and to be used in combination with other immunotherapies or conventional therapies such as radiotherapy and chemotherapy to augment efficacy. 相似文献
16.
Guidance Development Review Committee Working Group for Clinical Studies of Cancer Immunotherapy Working Group for Effector Cell Therapy Working Group for CMC/Non‐clinical Studies Working Group for Cancer Vaccines Adjuvants Working Group for Anti‐immune Checkpoint Therapy Comprehensive Cancer Immunotherapy Biostatistics Subcommittee 《Cancer science》2015,106(12):1761-1771
The development of cancer immunotherapies is progressing rapidly with a variety of technological approaches. They consist of “cancer vaccines”, which are based on the idea of vaccination, “effector cell therapy”, classified as passive immunotherapy, and “inhibition of immunosuppression”, which intends to break immunological tolerance to autoantigens or immunosuppressive environments characterizing antitumor immune responses. Recent reports showing clinical evidence of efficacy of immune checkpoint inhibitors and adoptive immunotherapies with tumor‐infiltrating lymphocytes and tumor‐specific receptor gene‐modified T cells indicate the beginning of a new era for cancer immunotherapy. This guidance summarizes ideas that will be helpful to those who plan to develop cancer immunotherapy. The aims of this guidance are to discuss and offer important points in early phase clinical studies of innovative cancer immunotherapy, with future progress in this field, and to contribute to the effective development of cancer immunotherapy aligned with the scope of regulatory science. This guidance covers cancer vaccines, effector cell therapy, and inhibition of immunosuppression, including immune checkpoint inhibitors. 相似文献
17.
《Annals of oncology》2014,25(2):322-331
Cytoreductive surgery and chemotherapy continue to be the mainstay of ovarian cancer treatment. However, as mortality from advanced ovarian cancer remains very high, novel therapies are required to be integrated into existing treatment regimens. Immunotherapy represents an alternative and rational therapeutic approach for ovarian cancer based on a body of evidence supporting a protective role of the immune system against these cancers, and on the clinical success of immunotherapy in other malignancies. Whether or not immunotherapy will have a role in the future management of ovarian cancer is too early to tell, but research in this field is active. This review will discuss recent clinical developments of selected immunotherapies for ovarian cancer which fulfil the following criteria: (i) they are antibody-based, (ii) target a distinct immunological pathway, and (iii) have reached the clinical trial stage. Specifically, the focus is on Catumaxomab (anti-EpCAM × anti-CD3), Abagovomab, Oregovomab (anti-CA125), Daclizumab (anti-CD25), Ipilimumab (anti-CTLA-4), and MXD-1105 (anti-PD-L1). Catumaxomab has reached phase III clinical trials and exhibits promise with reports, showing that it can cause a significant and sustained reduction in ascites. Phase I–III clinical trials continue to be conducted on the other antibodies, some of which have had encouraging reports. We will also provide our perspective on the future of immunotherapy for ovarian cancer, and how it may be best employed in treatment regimens. 相似文献
18.
Toyoshima K 《Gan to kagaku ryoho. Cancer & chemotherapy》2000,27(6):817-823
Various cancer immunotherapies are thought to be insufficient to suppress cancers by themselves. Thus, they are usually applied in cancer therapy as an immunopotentiator in combination with chemotherapy. However, chemotherapy itself seems to be hazardous for activated immune cells. On the other hand, immunotherapy after surgical treatment for cancer patients of stages I through III significantly reduced cancer deaths compared to historical control data for the same surgeon team. Some lymph node metastases are cured by immunotherapy after resection of the main tumors. The potential of immunocancer therapy and problems in the future development of new cancer therapies are discussed. 相似文献
19.
20.
《Annals of oncology》2018,29(3):588-601
Improved understanding of the interactions between cancer cells and the immune system combined with technological advances has led to the development of novel types of immunotherapies. These include checkpoint inhibitors, T-cell engager antibodies and chimeric antigen receptor T cells which have demonstrated remarkable efficacy in B-cell malignancies, including anti-PD1 antibodies in Hodgkin lymphoma, and T-cell engager antibodies and chimeric antigen receptor T cells in B-cell acute lymphoblastic leukemia, leading to their approval in these indications. Recent clinical data suggest that these immunotherapies may also benefit patients with other types of hematologic malignancies, particularly patients with Hodgkin and non-Hodgkin lymphomas. Here, we review the most recent clinical data regarding these different immunotherapies in patients with lymphoma. Ongoing and future studies should further define which immunotherapy may best apply to a given patient in order to provide a ‘personalized immunotherapy’. 相似文献